Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged with a high dose of the Zika virus.

.

Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study.

.

Zika DNA vaccine may protect against sexual transmission.

.PLYMOUTH MEETING, Pa. – June 7, 2017 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged with a high dose of the Zika virus.

.This preclinical study data was published in Nature Communications in an article entitled, “DNA Vaccination Protects Mice Against Zika Virus-Induced Damage to the Testes,” written by Inovio scientists and collaborators.

.

Dr. Gary Kobinger, lead author of the study and Director of the Centre for Research in Infectious Diseases at Laval University in Quebec City, Canada, said, “Given that we know that Zika virus infection can involve the male reproductive tract and persist in humans for several months after onset of infection, this preclinical data warrants further examination as a potential means to reduce Zika virus infection of the male reproductive tract and the risk of sexual transmission of the virus.”

.

Results from a previous preclinical study with GLS-5700 were published in Nature Partner Journals (npj) Vaccines and demonstrated that a single dose of Inovio’s Zika vaccine protected 100% of mice from infection, brain damage and death after exposure to the virus. Specifically, vaccinated mice were protected from degeneration in the cerebral cortex and hippocampal areas of the brain while un-vaccinated mice showed significant degeneration of the brain after Zika infection. In addition, a single dose of Inovio’s Zika vaccine also provided 100% protection from the virus in a study of non-human primates.

.

In the first-ever human study of a Zika vaccine, Inovio reported that in its phase I study (ZIKA-001), after a three dose vaccine regimen with GLS-5700 high levels of binding antibodies were measured (ELISA) in 100% (39 of 39) of evaluated subjects. Moreover, two doses or a single dose of vaccine generated a robust antibody response in 95% (37 of 39) and 40% (16 of 40) of evaluated subjects, respectively.

.Inovio’s second phase I study of 160 subjects in Puerto Rico (ZIKA-002) will complete enrollment this month. In this randomized, placebo-controlled, double-blind trial, 80 subjects received vaccine and 80 subjects received placebo. The study is evaluating the safety, tolerability and immunogenicity of GLS-5700 and assessing differences in Zika infection rates between the arms as an exploratory signal of vaccine efficacy.

.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “This published data suggests another avenue of potential protection against the Zika virus. While detrimental effects on sperm and fertility have not yet been reported in Zika-infected human males, persistence of Zika in semen and sperm and sexual transmission by males has been documented. This new preclinical data suggests that our Zika vaccine may represent an opportunity to limit the potential for sexual transmission of the virus. In addition to our ongoing ZIKA-001 and 002 clinical studies, we are planning for a larger phase 2 study in our efforts to bring our Zika vaccine to patients.”

.

Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the U.S. and Canada who are also collaborating to advance clinical development of Inovio’s Ebola and MERS vaccines.

.

About Zika Virus

First identified in Uganda in 1947, Zika virus subsequently spread to equatorial Asia and in recent years through the South Pacific, Hawaii, South America, Central America, and Caribbean. In 2016, local mosquito-borne transmission occurred in North America in Florida and Texas. Zika virus is a flavivirus, a family of viruses including yellow fever, dengue, and West Nile virus which are introduced to people through mosquito bites.

.Unlike other flaviviruses, Zika virus can be sexually transmitted. As of December 2016, 68 countries and territories reported continuing mosquito-borne transmission of the Zika virus, compared to 33 countries stated by WHO in their first Zika situation report in February 2016.

.

The most common symptoms of Zika virus infection are fever, rash, joint pain, and conjunctivitis. Zika is associated with birth defects, most notably microcephaly, which arise from infection during pregnancy. Microcephaly manifests as incomplete brain development and an abnormally small head. Recent reports suggest Zika may also be associated with other neurological abnormalities and abnormalities in other systems including ocular and cardiac. In adults Zika virus infection is associated with Guillain-Barre syndrome, which causes muscle weakness of the limbs and in severe cases may cause almost total paralysis including the inability to breathe.

.

No vaccine or therapy currently exists for the prevention or treatment of Zika virus infection.

.

About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favourable safety profile.

.With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar Institute, Laval University, University of Pennsylvania, Drexel University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program.

.

For more information, please visit www.inovio.com
CONTACT:
Bernie Hertel

+1 858-410-3101

bhertel@inovio.com

.

Barkerville Gold Mines Ltd. {TSX.V: BGM} announced additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company’s flagship Cariboo Gold Project.

The highlight is a new veining corridor at depth in the Valley Zone.

Barkerville Gold discovers new veining corridor at depth at the valley Zone.

.
BGM Intersects 12.43 g/t Au Over 7.20 Metres at Valley Zone

.

TORONTO, ON – June 6, 2017 – Barkerville Gold Mines Ltd. {TSX.V: BGM} is pleased to announce additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company’s flagship Cariboo Gold Project. The Company is currently exploring and delineating the Valley Zone with four drill rigs. Detailed drilling results, a drill hole location plan map, vertical section and longitudinal section are presented at the end of this release.

.

Drilling Highlights:
CM-17-015: 25.21 g/t Au over 2.00 metres
CM-17-015: 33.40 g/t Au over 1.50 metres
CM-17-018: 12.58 g/t Au over 5.50 metres
CM-17-023: 10.94 g/t Au over 7.85 metres
CM-17-023: 12.43 g/t Au over 7.20 metres
CM-17-023: 5.22 g/t Au over 19.55 metres
CM-17-024: 7.20 g/t Au over 9.05 metres
* The geometry and hence true width of the mineralized zones cannot be assuredly concluded at this time and as such, core lengths are reported.

.
New Mineralised Corridors Discovered at Depth in Valley Zone

Deeper drilling at the Valley Zone, which has not been explored circa 1960 has again yielded new, previously unidentified veining corridors. Drillhole CM-17-023 intersected three separate veining occurrences grading 10.94 g/t Au over 7.85 metres, 12.43 g/t Au over 7.20 metres and 5.22 g/t Au over 19.55 metres at respective depths of 270 metres, 310 metres and 375 metres vertically below surface.

.

On the same vertical section and located 50 metres above CM-17-023, drillhole CM-17-018 intersected 5.46 g/t Au over 5.20 metres, 12.58 g/t Au over 5.50 metres and 11.57 g/t Au over 2.00 metres and indicates a positive correlation with respect to continuity.CM-17-018 also intersected 13.92 g/t Au over 2.00 metres followed by 8.16 g/t Au over 4.00 metres in another new separate corridor 55 metres northwest of the former. These new corridors are open for expansion in all directions.

.

“The drill results in the Valley Zone continue to reaffirm our geological understanding of the Caribou Gold Project”, commented Matt Filgate, Senior Project Geologist. “We are beginning to see continuity between the Island Mountain and Cow Mountain areas through both shallow and deep drill intercepts, which is allowing us to better target areas of potential mineralisation.”

.
About the Phase II Program

The 130,000 metre 2017 Phase II exploratory and delineation drill program on Island Mountain is intended to determine the extent of the vein systems that were historically never explored, and is aimed at discovering new vein systems and sulphide replacement bodies that will ultimately inform a maiden resource at Island Mountain. Four drill rigs are currently delineating additional mineralisation below the former Aurum and Cariboo Gold Quartz Mines which have never been explored since mining operations ceased circa 1960.

.

Qualified Persons

Exploration activities at the Cariboo Gold Project are administered on site by the Company’s Exploration Manager, Maggie Layman, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical and scientific content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company’s secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by the Company’s Qualified Person, Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to ALS Geochemistry’s analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 250 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 0.01 ppm and upper limit of 100 ppm. Samples with gold assays greater than 100 ppm are re-analyzed using a 1,000g screen metallic fire assay. A selected number of samples are also analyzed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP- AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

.

For further information on Barkerville Gold Mines Ltd. please contact:

Chris Lodder
President & Chief Executive Officer
155 University Avenue, Suite 1440
Toronto, Ontario, Canada
clodder@barkervillegold.com

About Barkerville Gold Mines Ltd.
The Company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. Barkerville’s mineral tenures cover 2,110 square kilometres along a strike length of 67 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by Barkerville in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of material milled producing 25,464 ounces of gold. The Company has completed several drilling and exploration programs over the past 20 years and has compiled this data with all historical information in order develop geologic models which are assisting management in defining new deposits in the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

.
Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange (‘TSXV’) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

.

Table 1: Length weighted gold composites for Valley Zone drillholes:

HOLE-ID FROM (M) TO (M) CORE LENGTH (M) AU (G/T) AREA
CM-17-015 84.00 86.00 2.00 25.21 VALLEY
INCLUDING 84.50 86.00 1.50 33.40 VALLEY
CM-17-015 245.60 246.15 0.55 19.10 VALLEY
CM-17-015 279.70 280.60 0.90 10.15 VALLEY
CM-17-016 ABANDONED VALLEY
CM-17-017 85.65 86.15 0.50 16.50 VALLEY
CM-17-018 313.00 313.50 0.50 7.24 VALLEY
CM-17-018 327.00 328.00 1.00 59.20 VALLEY
CM-17-018 460.30 460.90 0.60 12.60 VALLEY
CM-17-018 467.30 472.50 5.20 5.46 VALLEY
INCLUDING 467.30 467.80 0.50 7.88 VALLEY
AND 470.90 471.70 0.80 7.53 VALLEY
AND 471.70 472.50 0.80 21.60 VALLEY
CM-17-018 480.00 485.50 5.50 12.58 VALLEY
INCLUDING 480.00 480.50 0.50 21.50 VALLEY
AND 480.50 481.00 0.50 18.25 VALLEY
AND 481.00 481.60 0.60 60.30 VALLEY
AND 484.50 485.00 0.50 17.15 VALLEY
CM-17-018 491.00 493.00 2.00 11.57 VALLEY
INCLUDING 491.00 492.00 1.00 6.53 VALLEY
AND 492.00 493.00 1.00 16.60 VALLEY
CM-17-018 509.40 510.00 0.60 10.10 VALLEY
CM-17-018 543.00 545.00 2.00 13.92 VALLEY
CM-17-018 559.00 563.00 4.00 8.16 VALLEY
INCLUDING 559.00 559.50 0.50 18.20 VALLEY
AND 560.00 560.50 0.50 29.70 VALLEY
AND 562.50 563.00 0.50 8.02 VALLEY
CM-17-019 ABANDONED
CM-17-020 ABANDONED
CM-17-021 ASSAYS PENDING VALLEY
CM-17-022 38.00 38.50 0.50 23.60 VALLEY
CM-17-023 125.85 126.35 0.50 68.50 VALLEY
CM-17-023 322.80 324.00 1.20 11.70 VALLEY
CM-17-023 369.05 376.90 7.85 10.94 VALLEY
INCLUDING 373.70 374.45 0.75 9.34 VALLEY
AND 374.95 375.65 0.70 77.60 VALLEY
AND 376.40 376.90 0.50 37.80 VALLEY
CM-17-023 417.80 425.00 7.20 12.43 VALLEY
INCLUDING 422.50 423.15 0.65 7.68 VALLEY
AND 423.15 423.65 0.50 158.00 VALLEY
CM-17-023 443.80 444.30 0.50 11.75 VALLEY
CM-17-023 483.90 484.50 0.60 15.35 VALLEY
CM-17-023 485.50 486.00 0.50 21.80 VALLEY
CM-17-023 493.50 494.00 0.50 12.65 VALLEY
CM-17-023 499.20 518.75 19.55 5.22 VALLEY
INCLUDING 499.20 499.70 0.50 28.80 VALLEY
AND 501.55 502.15 0.60 61.70 VALLEY
AND 509.30 510.15 0.85 14.80 VALLEY
AND 513.30 513.95 0.65 29.30 VALLEY
AND 518.25 518.75 0.50 17.90 VALLEY
CM-17-024 117.30 118.00 0.70 7.18 VALLEY
CM-17-024 167.75 176.80 9.05 7.20 VALLEY
INCLUDING 170.85 171.35 0.50 101.00 VALLEY
AND 173.00 173.80 0.80 8.66 VALLEY
CM-17-024 324.80 325.30 0.50 8.77 VALLEY
CM-17-024 571.00 571.65 0.65 32.30 VALLEY
CM-17-025 ASSAYS PENDING VALLEY
CM-17-026 212.50 213.00 0.50 7.41 VALLEY
CM-17-026 252.85 253.60 0.75 21.70 VALLEY
CM-17-026 275.20 276.10 0.90 7.08 VALLEY
CM-17-026 324.70 325.50 0.80 17.00 VALLEY
CM-17-026 344.25 350.00 5.75 8.36 VALLEY
INCLUDING 344.25 345.00 0.75 19.50 VALLEY
AND 345.00 345.60 0.60 25.80 VALLEY
AND 345.60 346.20 0.60 9.50 VALLEY
AND 349.35 350.00 0.65 13.50 VALLEY
CM-17-026 354.55 355.40 0.85 7.86 VALLEY
CM-17-026 380.15 380.95 0.80 13.30 VALLEY
CM-17-026 509.00 510.30 1.30 11.50 VALLEY
CM-17-028 162.55 164.70 2.15 17.61 VALLEY
INCLUDING 163.55 164.20 0.65 16.05 VALLEY
AND 164.20 164.70 0.50 13.80 VALLEY
CM-17-028-1 178.90 179.50 0.60 5.94 VALLEY
CM-17-028-1 197.25 198.15 0.90 5.44 VALLEY
CM-17-028-2 255.80 256.45 0.65 20.90 VALLEY
CM-17-028-2 260.70 261.20 0.50 48.80 VALLEY
CM-17-028-2 261.85 263.00 1.15 21.40 VALLEY
CM-17-028-2 271.30 271.80 0.50 16.80 VALLEY
CM-17-028-2 271.80 272.30 0.50 19.40 VALLEY
CM-17-028-2 274.35 275.05 0.70 7.55 VALLEY

* True widths cannot be accurately determined from the information available therefore core lengths are reported. Rock not recovered by drilling was assigned zero grade. Top cuts have not been applied to high grade assays. MC = Mosquito Creek, SHAFT = Shaft Zone, VALLEY = Valley Zone.

Table 2: Drillhole Collar Orientations:

HOLE-ID AZIMUTH DIP
CM-17-015 311.20 -61.10
CM-17-017 309.20 -41.10
CM-17-018 307.50 -42.70
CM-17-022 312.00 -57.90
CM-17-023 306.50 -45.20
CM-17-024 308.40 -44.40
CM-17-026 310.00 -45.00
CM-17-028 310.00 -45.00
CM-17-028-1 310.00 -45.00
CM-17-028-2 310.00 -45.00

…

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV).

Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

FDA removes clinical hold on phase 3;
Inovio to immediately begin recruiting subjects.

.
PLYMOUTH MEETING, Pa. – June 8, 2017 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV). Inovio’s study will assess the efficacy of VGX-3100 in regressing cervical HSIL (high-grade squamous intraepithelial lesions), a direct precursor to cervical cancer, and eliminating the HPV infection that causes these lesions. The pivotal data from this program will support the potential licensure of VGX-3100 as the first immunotherapy for this disease.

Inovio satisfied the FDA’s request for information relating to its CELLECTRA® 5PSP delivery device, resulting in the FDA removing the clinical hold on this program. Inovio plans to immediately begin recruiting patients for the phase 3 trial.

Inovio’s phase 3 program, named REVEAL (Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL), will consist of a primary study (REVEAL 1) and confirmatory study (REVEAL 2), as per FDA general guidance for phase 3 programs, to be conducted in parallel. The studies will each enroll 198 patients in more than 100 study centers globally. Mark Einstein, MD, MS, FACS, FACOG, Professor and Chair Department of Obstetrics, Gynecology and Women’s Health Assistant Dean, Clinical Research Unit, Rutgers New Jersey Medical School, is Principal Investigator for the studies.

The REVEAL studies are prospective, randomised (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical HSIL, otherwise known as cervical intraepithelial neoplasia (CIN) 2 or 3. The primary endpoint is regression of cervical HSIL AND virologic clearance of HPV-16 and/or HPV-18 in the cervix. The studies will evaluate cervical tissue changes at approximately 9 months after beginning a three dose regimen of VGX-3100 administered at months 0, 1, and 3. Secondary endpoints include safety; tolerability; regression of CIN 2/3 to CIN 1 or normal; virologic clearance of HPV; efficacy measured by non-progression to cancer; and clearance of HPV from non-cervical anatomic locations.

VGX-3100 has the potential to be the first treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. VGX-3100 stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and destroying pre-cancerous cells. There are no treatments available for HPV infection and surgery is the only approved treatment for cervical HSIL. While surgery is effective at removing dysplastic lesions, it does not treat the underlying HPV infection and carries increased risk of cervical incompetence and pre-term birth, which can result in fetal morbidity and mortality. VGX-3100 demonstrated in a phase 2b study (published in The Lancet) its ability to clear HPV-16 and HPV-18 infection and pre-cancerous lesions.

Dr. Mark Bagarazzi, Inovio’s Chief Medical Officer, said, “Despite the availability of preventive HPV vaccines for over a decade, HPV-related cervical HSIL and cancers remain a widely prevalent problem. Unfortunately, current treatments are invasive and do not address the underlying HPV infection. VGX-3100 has the potential to be a first-in-class HPV-specific immunotherapy offering women the prospect of preventing cervical cancer without undergoing an invasive surgical procedure that may compromise their reproductive health. We are pleased to be able to immediately begin recruiting patients at the first 15 sites by the end of this month.”

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “Initiating our REVEAL phase 3 program marks a milestone for Inovio, for the next generation of DNA-based immunotherapies, and for women’s health. Combining this first phase 3 program with our previously announced phase 2 clinical trial of VGX-3100 for HPV-related vulvar neoplasia and our checkpoint inhibitor-based combination study with MedImmune/AstraZeneca targeting HPV associated cancers, Inovio is well positioned to comprehensively treat HPV-associated diseases across the continuum of HPV infection through to cancer in both men and women. Adding our recently announced collaborative immuno-oncology combination studies with Regeneron and Genentech, 2017 is a transformative year that is laying the foundation for multiple opportunities for important efficacy data.”
About HPV and Cervical HSIL

HPV is the most common sexually transmitted infection, with over 14 million new infections annually. While many of these are transient infections, persistent high-risk infections can cause the formation of pre-cancerous lesions. Left untreated, women diagnosed with cervical HSIL are at increased risk of developing cervical cancer. HPV types 16 and 18 are responsible for 70% of cervical cancers, with more than 400,000 new cases of HPV 16/18 cervical HSIL annually in the US and Europe. Cervical cancer is a major global health problem, causing 260,000 deaths annually. While cervical HSIL and cervical cancer are the most well-known HPV related diseases, HPV is also a major cause of HSIL and cancer in the entire anogenital region and oropharynx. Currently there are no treatments available for HPV infection and surgery is the only approved treatment for cervical HSIL. While surgery is effective at removing lesions, it does not treat the underlying HPV infection and it carries increased risk of cervical incompetence and pre-term birth, which can result in fetal morbidity and mortality.
About VGX-3100

VGX-3100 is a DNA-based immunotherapy under investigation for the treatment of HPV-16 and HPV-18 infection and pre-cancerous lesions of the cervix (phase 3) and vulva (phase 2). VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of pre-cancerous cells. In a randomized, double-blind, placebo-controlled phase 2b study in 167 adult women with histologically documented HPV 16/18 cervical HSIL (CIN2/3), treatment with VGX-3100 resulted in a statistically significantly greater decrease in cervical HSIL and clearance of HPV infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. VGX-3100 utilizes the patient’s own immune system to clear HPV-16 and HPV-18 infection and pre-cancerous lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial impacts.
About Inovio’s DNA Immunotherapy Technology Platform

Inovio is advancing the medical potential of a unique class of immunotherapy technology. Its DNA-based platform, which is the foundation for all of Inovio’s products, including VGX-3100, is unique in its ability to leverage the body’s naturally existing mechanisms to generate robust, highly targeted immune responses to prevent and treat disease – and to do so in the body without harmful side effects. Its SynCon® immunotherapy design and CELLECTRA® delivery transform novel genetic blueprints into functional antibody and killer T cell responses. Inovio was the first to report the activation – in the body – of significant, antigen-specific functional T cells correlated to statistically significant efficacy in a placebo-controlled, randomized, double-blind phase 2b clinical trial (HPV-related pre-cancer), with a very favorable safety profile. These data were published in The Lancet and independently described as a “major breakthrough” in the field by U.S. National Cancer Institute scientists. Inovio has achieved significant antigen-specific immune responses against multiple diseases and is advancing a growing pipeline of cancer and infectious disease immunotherapies and vaccines.
About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favourable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar Institute, Laval University, University of Pennsylvania, Drexel University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program.

For more information, visit www.inovio.com

CONTACT:
Bernie Hertel

+1 858-410-3101

bhertel@inovio.com

# # # #

This press release contains certain forward-looking statements relating to our business, including our plans to conduct phase 3 clinical trials for VGX-3100 for the treatment of cervical dysplasia caused by HPV, a phase 2 clinical trial of VGX-3100 for HPV-related vulvar neoplasia and other immuno-oncology combination studies. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the availability and timing of data from ongoing clinical trials, uncertainties inherent in the completion of ongoing clinical trials and the initiation of future clinical trials, whether the results of earlier clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, the availability of funding to support continuing research and studies, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop and other factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2017, our Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 10, 2017, and other filings that Inovio makes with the SEC from time to time. There can be no assurance that any product candidate in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

In addition, the forward-looking statements included in this press release represent Inovio’s views as of the date hereof. Inovio anticipates that subsequent events and developments may cause its views to change. However, while Inovio may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing Inovio’s views as of any date subsequent to the date of this release.

.

Strongbow Exploration Inc. (TSX-V: SBW),  announced that Siltbuster Process Solutions Ltd. and Nomenca Ltd.have been engaged to undertake Process Specification and Outline Design Works for a water treatment plant at Strongbow’s South Crofty project located in Cornwall, UK.

Keith Russ, a technical service engineer of the South Crofty Tin Project, stands in a mining tunnel at South Crofty tin mine in Redruth, U.K., on Thursday, Aug. 11, 2016. Strongbow Exploration Inc., who the bought mine last month, could have the mine in production by 2019 or 2020, delivering 20 tons of tin a day, according to Chief Executive Officer Richard Williams. Photographer: Simon Dawson/Bloomberg

.

Strongbow Engages Engineering Firms For Water Treatment Plant Design At The South Crofty Tin Project, Cornwall, UK

Strongbow Exploration Inc. (TSX-V: SBW),  is pleased to announce that Siltbuster Process Solutions Ltd. (“SPS”) and Nomenca Ltd. (“Nomenca”) have been engaged to undertake Process Specification and Outline Design Works for a water treatment plant at Strongbow’s South Crofty project located in Cornwall, UK.

.

Strongbow successfully completed water treatment trials in March 2017 and subsequently has submitted an application to the Environment Agency for a mine water discharge permit. Upon receipt of the water discharge permit, the project will be fully permitted.

.

The water treatment plant will be designed to treat 25,000 cubic metres of mine water per day and enable dewatering of the mine workings in the South Crofty project area.

.

Richard Williams, the Company’s CEO, commented: “This is an important step in the development of our South Crofty project and will enable Strongbow to begin construction of the water treatment plant, subject to financing, as soon as we receive the discharge permit from the Environment Agency. The Company expects to receive the discharge permit later this year, and commence dewatering of the mine in the first half of 2018, as planned.”

.

SPS, based in Monmouthshire, UK, was responsible for overseeing the recent successful water treatment trials at South Crofty. SPS has extensive experience in the design, construction and operation of mine water treatment plants, including plants at Wheal Jane, Hemerdon, Dawdon (all in the UK) and Strieborná in Slovakia. SPS will be responsible for providing the process specifications for the plant and the outline design. They will also provide technical support during the detailed engineering and construction phases and be responsible for commissioning the plant.

.

Nomenca, based in St. Austell, UK is a subsidiary of North Midland Construction Plc and operates in a variety of industries as a specialist Mechanical, Electrical, Instrumentation, Control and Automation (MEICA) Contractor providing consultancy services, design and construction, operation and maintenance of assets. Nomenca has extensive experience in both the mining and water treatment sectors having undertaken multiple projects for Imerys, Wolf Minerals and South West Water. Nomenca will initially be undertaking target costing and outline design works for the treatment plant, which is expected to lead into the detailed engineering and construction phases.

.

About South Crofty

The South Crofty project includes a past-producing underground tin mine located in Cornwall, UK. Mining in the area dates back approximately 400 years. Mining at South Crofty ceased in 1998, following 13 years of sustained low metal prices. The South Crofty project has a valid mine permit (until 2071) with surface and underground planning permissions.

.

Strongbow acquired South Crofty in July 2016 and has since published a NI 43-101 mineral resource estimate, see report for details, and a Preliminary Economic Assessment (“PEA”) on February 16, 2017. The mine is presently flooded but recent water treatment trials have demonstrated that the water can be successfully treated to a quality sufficient to permit safe dewatering of the mine. A water discharge permit application was lodged with the Environment Agency in April 2017 and is expected to be awarded in September 2017, which should enable mine dewatering to commence in Q2 2018.

.

Radisson Mining Resources Inc. (TSX.V: RDS} announced that the six candidates designated in the management proxy circular dated May 9, 2017 were elected to the Corporation’s Board of Directors during the shareholder’s annual meeting held in Rouyn-Noranda on June 2, 2017.

Radisson Announces AGM Results, engages Mackie Research to improve liquidity

.

ROUYN-NORANDA, QUEBEC  June 5, 2017) – Radisson Mining Resources Inc. (TSX.V: RDS} announces that the six candidates designated in the management proxy circular dated May 9, 2017 were elected to the Corporation’s Board of Directors during the shareholder’s annual meeting held in Rouyn-Noranda on June 2, 2017.

 
The shareholders were represented in person or by proxy by 39,494,740 class A shares, or 36.71% of the 107,594,357 outstanding class A shares.

.

Voting results are presented below.
2017 AGM Election of Directors Results
Director For % For Withheld % Withheld
Mario Bouchard 38,533,034 97.56 % 961,706 2.44 %
Jean Dion 38,479,621 97.58 % 957,306 2.42 %
Jean-Marie Dupont 38,323,934 97.04 % 1,170,806 2.96 %
Denis Lachance 39,491,240 99.99 % 3,500 0.01 %
Luc Simoneau 38,479,621 97.58 % 957,306 2.42 %
Réjean Gourde 38,537,434 97.58 % 957,306 2.42 %

.
Consequently, during the shareholder’s annual meeting, the appointment of Deloitte S.E.N.C.R.L/s.r.l as Independent auditor for the company was approved at 100% by the shareholders.

.
Grant of stock options
On June 2nd 2017, the Board of Directors awarded a total of 790,000 stock options to directors, officers and one employee of the company. Pursuant to terms of the stock options plan each option grants the holder thereof the right to purchase one class A share at a price of $ 0.165 until June 2nd, 2022. Following the grant of stock options and pursuant to terms of the stock options plan, there are currently 2,935,000 stock options outstanding.

.
The company announces the exercise of 300,000 stock options by two directors, resulting in the emission of 300,000 class A shares at a price of $ 0.10. As a result of this stock option exercise, there are currently 107,594,357 class A shares of Radisson issued and outstanding.

.
The company announces it has retained Mackie subject to regulatory approval; it has retained Mackie Research Capital Corporation to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation.

.

Mackie will trade shares of Radisson on the TSXV for the purposes of maintaining a reasonable market and improving the liquidity of Radisson’s class A shares. The agreement between Mackie and the Company is for a minimum 3 months term and the Company has agreed to pay Mackie $4,000 per month during the term, payable quarterly in advance. After the 3 months period, either party with written notice of 30 days may terminate the engagement. The Company and Mackie act at arm’s length and there are no performance factors contained in the agreement between Mackie and the Company and Mackie will not receive any shares or options from the Company as compensation for services it will render.

 
About Radisson Mining Resources Inc.
Radisson is a Quebec-based mineral exploration company. The O’Brien project, cut by the regional Larder-Lake-Cadillac Fault, is Radisson’s main asset. The former O’Brien Mine, is considered to have been the Abitibi Greenstone Belt’s highest-grade gold producer during its production (1,197,147 metric tons at 15.25 g/t Au for 587,121 ounces of gold from 1926 to 1957; InnovExplo, April 2015).

.

For more information on Radisson, please visit our website at www.radissonmining.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

.
Forward-Looking Statements: This press release may contain certain forward-looking information. All statements included herein, but other than statements of historical fact, is forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Radisson’s disclosure documents on the SEDAR website at www.sedar.com

.

.
CONTACT INFORMATION
Radisson Mining Resources Inc.
Mario Bouchard
President & Chief Executive Officer
819-277-6578
mbouchard@radissonmining.com

.

Neometals Ltd {ASX: NMT} announced results from lithium battery cycling test work demonstrating the superior performance characteristics of its Lithium Titanate anode material. 

 In 2017, the Company engaged a leading US test facility to commence 100‐cycle cycle testing of coin cell batteries using Lithium Titanate (“LTO”) anode material made by the Company at the CSIRO.  

.

Successful ‘Proof of Concept’ Battery Cycle testing of   
Lithium Titanate 

.

Neometals Ltd {ASX: NMT} is pleased to announce results from lithium battery cycling test work demonstrating the superior performance characteristics of its Lithium Titanate anode material.  In 2017, the Company engaged a leading US test facility to commence 100‐cycle cycle testing of coin cell batteries using Lithium Titanate (“LTO”) anode material made by the Company at the CSIRO.

.
Lithium Titanate is a leading anode (negative electrode) material, which can replace
graphite.  Its primary advantage over graphite is the surface area of the anode of LTO
being around 100 square metres per gram in contrast to typically 3 square metres for
graphite.  The enlarged surface area enables electronsto enter and leave the anode much
more rapidly, leading to ultrafast recharging, enhanced battery life and enhanced safety
performance (practical elimination of thermal runaway).

.
Trial material was made from commercial reagents and future test programs will test
material made from compounds produced from the Company’s Barrambie Titanium
Project and Mt Marion Lithium Operation. Performance of anode material is expected to
improve with increased grade of raw material and finer particle size.

.

Test Results
‐ Two LTO samples made via different methods held higher voltage and current at start
and end of 100 cycles (425 hrs) as compared to commercially available LTO:
‐  Comparative Loss in Capacity in one sample was highly superior to commercially
available LTO.
The conceptual plan is to develop a process producing a superior Lithium Titanate anode
material from feedstocks generated from the Company’s captive resources.

.

The Company is developing multiple positions further down the Lithium‐Ion Battery supply
chain, consistent with its strategy to maximise returns from existing and future operations
by producing higher value products.  The Company’s lithium strategy is represented in the
following illustration.

Next Steps
The Company recognises the importance of using long‐term cycling data in order to
characterise the sustainability of battery performance and plans future cell testing of
Barrambie/Mt Marion based LTO materials to be scaled up to 500 cycles.

.

Subject to technical opinions the Company will seek protection of IP and commence discussions with potential commercialisation partners.

ENDS
For further information, please contact:
Chris Reed
Managing Director
Neometals Ltd
+61 8 9322 1182
info@neometals.com.au

Nouveau Monde Graphite {TSX.V: NOU} We are pleased to announce that NOU will present to our investor group on Thursday 7th June at St. Pauls in London, in a luncheon presentation. NOU are a flake graphite exploration and development company based in Quebec, Canada.

All are welcome to attend, please email andrew@city-investors-circle.com to reserve your place.

.

Nouveau Monde Graphite {TSX.V: NOU} We are pleased to announce that Eris Desaulniers, CEO and President of Nouveau Monde Graphite  will present to our investor group on Thursday 7th June at the Cote Brasserie at St. Pauls in London, in a luncheon presentation.

.

NOU are a flake graphite exploration and development company based in Quebec, Canada.

.

NOU plan to commence production at a 1,000 ton per annum pilot plant in early 2018.

.

All are welcome to attend, please email andrew@city-investors-circle.com to reserve your place.

Colonial Coal International Corp. {TSX.V: CAD} has recently concluded negotiations to acquire 3-D seismic data covering approximately 32.51 square kilometres of the company’s Flatbed coking coal property.

The seismic data extend through the upper, coal-bearing sections of the stratigraphic succession that underlies the property and covers one of the main target areas.

Colonial Coal reviewing Flatbed seismic data acquired

2017-05-31 17:52 ET – News Release

Mr. David Austin reports

COLONIAL COAL INTERNATIONAL CORP. PROVIDES CORPORATE UPDATE

Colonial Coal International Corp. {TSX.V: CAD} has recently concluded negotiations to acquire 3-D seismic data covering approximately 32.51 square kilometres of the company’s Flatbed coking coal property.

.

The seismic data extend through the upper, coal-bearing sections of the stratigraphic succession that underlies the property and covers one of the main target areas. This target area was one of several identified by an independent consultant’s review of the property (previously announced on Jan. 28, 2013) and forms the prime focus for drilling this summer.

.

Initial evaluation and interpretation of the seismic data are now under way. The primary purpose of this work is to confirm drill targets and refine coal seam depth estimates for exploration budget purposes.

.

Company staff is moving ahead with exploration planning, particularly in regard to contractor selection, contract preparation, and ensuring adherence to all government permit regulations and requirements. A site visit is planned shortly to assess field conditions and to lay out an arterial exploration trail.

.

In addition, recent corporate activities, undertaken in conjunction with the company’s investor relations consultant, O&M Partners, have included:

• A marketing trip along the eastern seaboard of the United States, during which multiple presentations were made to current and prospective shareholders, fund managers, and brokers;
• One town hall style meeting, conducted by telephone, for similar participants; with further town hall meetings being scheduled for the future.

.

This news release has been reviewed by John Perry, a director of the company and a qualified person as defined in National Instrument 43-101.

.

About Colonial Coal International Corp.

Colonial Coal is a publicly traded coal corporation in British Columbia that focuses primarily on coking coal projects. The northeast coal block of British Columbia, within which the corporation’s projects are located, hosts a number of proven deposits and has been the subject of merger-and-acquisition activities by Xstrata, Walter Energy, Anglo-American and others.

.

Nouveau Monde {TSX.V: NOU} – A Quebec based graphite exploration and development company is going to present to the Circle on Wednesday 7th June, in a lunchtime presentation at St. Pauls.

Anyone wishing to attend should email andrew@city-investors-circle.com 

.

Nouveau Monde {TSX.V: NOU} – A Quebec based graphite exploration and development company is going to present to the Circle on Wednesday 7th June, in a lunchtime presentation at the Cote Brasserie, Ludgate Hill. St. Pauls.

.

Anyone wishing to attend should email andrew@city-investors-circle.com 

.

Full details will be sent by return.

.

Neometals Ltd {ASX: NMT} announced outstanding results of testwork on a titanium‐based adsorbent, developed by the Company, which has the potential to deliver a more cost effective and environmentally friendly method of extracting lithium and potassium from sodium rich brines as compared to traditional solar evaporation.  

Successful ‘Proof of Concept’ testing of Direct Lithium and
Potassium Extraction from Brines  

.

Neometals Ltd {ASX: NMT} is pleased to announce outstanding results of testwork on a titanium‐based adsorbent, developed by the Company, which has the potential to deliver a more cost effective and environmentally friendly method of extracting lithium and potassium from sodium rich brines as compared to traditional solar evaporation.

.
Testwork conducted by a leading independent Australian research facility has confirmed that Neometals’ adsorbent technology is able to successfully recover lithium and potassium from salar brines while rejecting all of the sodium in solution.

.

The continuous cycle testing demonstrates that the technology has the potential to replace the sodium removal by the conventional solar evaporation process stage used in typical brine processing flowsheets, such as those used in the Andes region of South America.
The conventional solar evaporation phase requires significant capital expenditure to
construct a series of large evaporation ponds, significant maintenance of the operating
ponds to harvest and store salt and has an approximate 12 months processing period.
Water in the brine that has been extracted from aquifers and salars is lost to the
atmosphere through evaporation.

.
In comparison, the Proof of Concept test results indicate that lithium and potassium
adsorption, and rejection of sodium, could be conducted using conventional process
equipment with residence times of less than 30 minutes. Returning nearly all of the brine
volume to the salar allows exploitation of salar aquifers with anticipated minimal impact
on the water table.

.

.
Test Results
Synthetic and natural brine samples were used in bench scale laboratory testing at a
leading independent Australian research facility. Research and development work since
2015 has resulted in:
‐ the complete rejection (100%) of sodium in the brine by the adsorbent material
‐ in the adsorption phase lithium recovery ranging from 53‐79% and potassium recovery
from 36‐45%.  The balance is returned to the salar for future extraction.
‐ Equilibrium adsorption (loading) was typically 5‐15 minutes and desorption (stripping)
was 5‐10 minutes in the cycle testing phase.    Adsorbent readily separated from the
aqueous phase using conventional solid/liquid separation methods.
Trial adsorbent has been made from commercial reagents and from titanium compounds
produced from the Company’s Barrambie Titanium Project test program. Performance of
adsorbent material appears to improve with increased grade of raw material and the
Barrambie test product appears to deliver superior adsorbent performance.
The conceptual plan is to return “stripped” brine to the salar or aquifer and use a large
processing volume coupled with short cycle time to extract lithium/potassium on a
suitable scale.  The Company is also evaluating other technologies that can be coupled
with the adsorption technology in an integrated flow sheet that completely replaces the
salt removal and brine concentration/purification phases used in conventional brine flow
sheets.

.

.
Neometals Managing Director, Chris Reed, commented: “Proving this scalability of this
technology will have significant implications for brine‐based producers and developers,
who hold seventy‐five percent of the world’s lithium resources.  Increasing the speed and
yield of lithium extraction from brines and reducing operating and capital costs are the
keys to unlocking supply needed to meet the lithium demands of the next decade. ”

.
Next Steps
The Company has filed a Provisional Patent and PCT Application. Its strategy is to develop related technologies and commercialise the technologies with suitable partners. The commercial strategy is licence the technology for royalties and to retain the right to
deploy it as principal.

.

The Company will keep the market updated on all material developments with commercialisation partners.

.

ENDS

.

.
For further information, please contact:
Chris Reed
Managing Director
Neometals Ltd
+61 8 9322 1182
info@neometals.com.au

Neometals {ASX: NMT} – The London presentation on Tuesday 6th June is now full.

There is no awaiting list for this event.

Neometals {ASX: NMT} – The London presentation on Tuesday 6th June is now full.

There is no awaiting list for this event.

Neometals is always a popular company when they visit London as this has been a real turnaround story, from the verge of running out of money to becoming a profitable lithium miner and exporter in the space of a few years.

Please email andrew@city-investors-circle.com if you would like a handout of the presentation.

Zenyatta Ventures {TSX.V: ZEN} announced that the next phase to test a concrete admixture containing graphene is progressing through their Collaboration Agreement with Larisplast Ltd., an Israeli business that specialises in the field of concrete admixtures.

Zenyatta’s Graphene Enhanced Concrete Pilot Project Advances with Larisplast and Ben-Gurion University in Israel

 
THUNDER BAY, ON- May 25, 2017) – Zenyatta Ventures {TSX.V: ZEN} is pleased to announce that the next phase to test a concrete admixture containing graphene is progressing through their Collaboration Agreement with Larisplast Ltd. (“Larisplast”), an Israeli business that specializes in the field of concrete admixtures.

The 10 kg market sample of high-purity graphite that was sent to Ben-Gurion University of the Negev in Israel will allow for the testing and optimization of a much larger volume of concrete which could be in a range between 5 and 10 tonnes. Zenyatta and Larisplast have both received grant funding from the Canada-Israel Industrial R&D Foundation under the Ontario-Israel Collaboration.

The main objective of this pilot plant is to further test a much larger volume of concrete utilizing an admixture containing Albany derived graphene . The scientific and engineering data obtained will yield valuable information for potentially designing a larger scale demonstration plant. In 2016 BGU demonstrated that the addition of the Company’s graphene into concrete can achieve a faster curing time and a superior mechanical performance that inhibits premature failure and tolerates large forces like those produced during earthquakes or explosions. Also, this new admixture has the potential to reduce the amount of cement that will be used in construction, thereby considerably cutting carbon dioxide emissions related to its production.

 
Aubrey Eveleigh, President and CEO stated, “We are pleased to be in the next stage of testing to demonstrate the viability of this exciting technology to enhance concrete properties with nano-graphite derived from Zenyatta’s Albany deposit. This initiative represents an important new and valuable target market for Albany graphite as the potential market size for a new concrete admixture with superior qualities is extremely large.”

 
In November 2016 Zenyatta delivered 10 kilograms of high-purity Albany graphite to BGU that has now been converted to graphene for optimisation and testing. BGU will first test the graphene and then the material will be supplied to Larisplast for testing as a concrete admixture.

• The testwork will include the following:
  BGU will perform a variety of quality control measurements;
  BGU will run a series of dispersion experiments on Zenyatta’s graphene;
  Larisplast and BGU will employ the optimised procedure using scaled-up infrastructure;
  The optimised graphene dispersion will then be incorporated into concrete composites;
  The produced graphene reinforced concrete will be tested for both short and long term strength and compressive and flexural stresses;
  Larisplast will adjust and optimize the scaled-up process.

 
About Larisplast

Larisplast is an industry leader in Israel specializing in the field of concrete admixtures. The company develops, produces, markets and distributes high-quality products and materials for the Israel concrete industry according to strict Israeli’s standards. Larisplast operates on a nationwide basis in Israel and is currently developing international markets and distribution channels.

 
About Zenyatta

Zenyatta is developing the Albany Graphite Deposit situated in northeastern Ontario, Canada. The deposit is a unique type of igneous-hosted, fluid-derived graphite mineralisation contained in two large breccia pipes. The Company is seeking end users for their graphite and graphene and is working with several collaborative partners including the development of a graphene enhanced concrete. Other potential markets for graphite include Lithium-ion batteries, fuel cells and powder metallurgy. The application for graphitic material is constantly evolving due to its unique chemical, electrical and thermal properties. It maintains its stability and strength under temperatures in excess of 3,000°C and is very resistant to chemical corrosion. It is also one of the lightest of all reinforcing elements and has high natural lubricating abilities. The outlook for the global graphite market is very promising with demand growing rapidly from new applications. It is now considered one of the more strategic elements by many leading industrial nations, particularly for its growing importance in high technology manufacturing and in the emerging “green” industries such as electric vehicle components.

 
The Albany graphite deposit is situated 30 km north of the Trans-Canada Highway, power line and natural gas pipeline near the communities of Constance Lake First Nation and Hearst. A rail line is located 70 km away with an all-weather road approximately 10 km from the graphite deposit. The world trend is to develop products for technological applications that need extraordinary performance using ultra-high purity graphite powder at an affordable cost. Albany graphite can be upgraded with very good crystallinity without the use of aggressive acids (hydrofluoric) or high temperature thermal treatment therefore having an environmental advantage over other types of upgraded high-purity graphite material.

 
Mr. Aubrey Eveleigh, P.Geo., Zenyatta’s President and CEO, is the “Qualified Person” for the purposes of National Instrument 43-101 and has reviewed, prepared and supervised the preparation of the technical information contained in this news release.

 
CAUTIONARY STATEMENT: This analysis does not represent a statistically large sample size. Furthermore, these positive results do not mean that Zenyatta can extract and process Albany graphite for graphite applications on an economic basis. Without a formal independent feasibility study, there is no assurance that the operation will be economic. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward looking information and Zenyatta cautions readers that forward looking information is based on certain assumptions and risk factors that could cause actual results to differ materially from the expectations of Zenyatta included in this news release. This news release includes certain “forward-looking statements”, which often, but not always, can be identified by the use of words such as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. These statements are based on information currently available to Zenyatta and Zenyatta provides no assurance that actual results will meet management’s expectations. Forward-looking statements include estimates and statements with respect to Zenyatta’s future plans, objectives or goals, to the effect that Zenyatta or management expects a stated condition or result to occur, including the expected timing for release of a pre-feasibility study, the expected uses for graphite in the future, and the future uses of the graphite from Zenyatta’sAlbany deposit. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, results of metallurgical processing, ongoing exploration, project development, reclamation and capital costs of Zenyatta’s mineral properties, and Zenyatta’s financial condition and prospects, could differ materially from those currently anticipated in such statements for many reasons such as, but are not limited to: failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the inability to identify target markets and satisfy the product criteria for such markets; the inability to complete a prefeasibility study; the inability to enter into offtake agreements with qualified purchasers; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets, inflation, changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in Zenyatta’s public documents filed on SEDAR. This list is not exhaustive of the factors that may affect any of Zenyatta’s forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on Zenyatta’s forward-looking statements. Although Zenyatta believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zenyatta disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

 
CONTACT INFORMATION

For Further Information, please visit the Company’s website at: www.zenyatta.ca

Bitcoin {BTC / XBT} After the recent price surge which has seen the recent price surge double the value of the coin in around a month, a sharp decline has occurred, knocking 30% of the $2,800 record price achieved only last Wednesday.

This is of course no surprise, and highlights the volatility in investing in crypto currencies.

Bitcoin suffers a 30% fall since last Thursday after the recent price surge.

Bitcoin {BTC / XBT} After the recent price surge which has seen the recent price surge double the value of the coin in around a month, a sharp decline has occurred, knocking 30% of the $2,800 record price achieved only last Wednesday.

This is of course no surprise, and highlights the volatility in investing in crypto currencies.

The decline seems to have been arrested for now,however, as the chart pasted below shows a small rebound on the technical support line.

Should the price fall through support then a larger fall may occur, so we shall monitor it for now.

It comes as no surprise that most of the other popular crypto currencies such as Ethereum, Dash, and Minero, have suffered similar falls in value, as the rising tide was carrying them up in tandem with Bitcoin.

Maybe the recent pull back will bring a reality check to some investors that have piled into Bitcoin as a one way easy money investment?  The price seemed to be losing touch with reality, in my opinion, afterall this is as much a fiat currency as the US$ or British pound is, there is no backing, just trust that the tokens can be exchanged for value when required.

Komet Resources Inc. {TSX.V: KMT}  announced the first drilling results on the Guiro South zone, 488 meters south to the Guiro mine.

CEO André Gagné  stated “the results are very encouraging for the future growth of mine production by the Company.”

.

Quebec City, May 25, 2017 – Komet Resources Inc. {TSX.V: KMT} is pleased to announce the first drilling results on the Guiro South zone, 488 meters south to the Guiro mine.

.

André Gagné, president and CEO declares: “We are very enthusiastic about this new discovery close to the Guiro mine and its facilities. Those results are very encouraging for the future growth of mine production by the Company.”.

.

Following the sampling results on this new zone announced in the March 29, 2017 press release, three holes were core drilled over an area of ​​40 m in width by 80 m in length and confirmed a striped and coiled vein that appears parallel and similar to the Guiro vein. These three holes intercepted the structure, but hole 1 did not contain the mineralised vein.

.

The two mineralised stacks encountered at 40 m depth have an average (true) width of 0.91 m and an average grade of 7.6 g/t Au. This grade is of the same order as that found in the grooves of gold pits (March 29, 2017 press release). Two visible gold points are present in Survey 2. Following those excellent results, a drilling campaign of at least 1000 meters is underway.

.

Summary table of the results from the mineralised zone:

Reminder of the results from the March 29, 2017 press release.

Summary of results from selected samples from gold panner’s bags:
(concentrated samples not representative of the mineralization hosted on the property)

Summary of results from perpendicular channel sampling:
(Channel length represents the full true width)

All assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company’s mine site laboratory. Quality Assurance/Quality Control and interpretation of results is performed by qualified persons employing a QA/QC program consistent with NI 43–101 and industry best practices, including the introduction of standards or blanks with every batch of 3 samples analysed.

.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: André Gagné, President and CEO 

.

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the technical information presented herein.

.

Forward-Looking Statements
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

.

.

Barkerville Gold Mines {TSXV: BGM} announced additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company’s flagship Cariboo Gold Project. The Company is currently exploring and delineating the Valley Zone with four drill rigs.

BGM INTERSECTS 24.13 G/T AU OVER 12.70 METRES AT MOSQUITO CREEK

.

Mosquito Creek Also Yields 49.79 g/t Au over 8.05 metres

.

TORONTO, ON – May 25th, 2017 – Barkerville Gold Mines {TSXV: BGM} is pleased to announce additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company’s flagship Cariboo Gold Project. The Company is currently exploring and delineating the Valley Zone with four drill rigs.

Replacement Mineralisation Intersected Northwest of Mosquito Creek

Located 160 metres down plunge of the former Mosquito Creek Mine at a vertical depth of 100 metres below surface, drillhole IM-17-100 intersected replacement mineralisation grading 24.13 g/t Au over 12.70 metres. This new faulted occurrence correlates 35 metres up plunge to previously reported Phase I drillhole BGM-16-553 which intersected 56.31 g/t Au over 4.10 metres.

New Veining Intersected Northwest of Mosquito Creek

Drillhole IM-17-107 intersected new auriferous quartz veining grading 49.79 g/t Au over 8.05 metres fifty metres vertically below surface. In this sparsely drilled area, the veining intersection is open for expansion in all directions.

The geometry and hence true width of the potential mineralised zones cannot be assuredly concluded at this time.

The Company’s Exploration Manager, Maggie Layman, P.Geo., commented, “The results from the Island Mountain drilling continue to demonstrate continuity, tenor and size potential of both replacement and vein style mineralisation at shallow depths. The Phase II exploration program on Island Mountain continues to reveal exceptionally high grade intercepts in new zones”.

About the Phase II Program

The 130,000 metre 2017 Phase II exploratory and delineation drill program on Island Mountain is intended to determine the extent of the vein systems that were historically never explored, and is aimed at discovering new vein systems and sulphide replacement bodies that will ultimately inform a maiden resource at Island Mountain. Four drill rigs are currently delineating additional mineralisation below the former Aurum and Cariboo Gold Quartz Mines which have never been explored since mining operations ceased circa 1960.

.
Qualified Persons

Exploration activities at the Cariboo Gold Project are administered on site by the Company’s Exploration Manager, Maggie Layman, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical and scientific content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company’s secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by the Company’s Qualified Person, Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to ALS Geochemistry’s analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 250 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 0.01 ppm and upper limit of 100 ppm. Samples with gold assays greater than 100 ppm are re-analyzed using a 1,000g screen metallic fire assay. A selected number of samples are also analyzed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

For further information on Barkerville Gold Mines Ltd. please contact:

Chris Lodder
President & Chief Executive Officer
155 University Avenue, Suite 1440
Toronto, Ontario, Canada

About Barkerville Gold Mines Ltd.

The Company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. Barkerville’s mineral tenures cover 2,110 square kilometres along a strike length of 67 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by Barkerville in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of material milled producing 25,464 ounces of gold. The Company has completed several drilling and exploration programs over the past 20 years and has compiled this data with all historical information in order develop geologic models which are assisting management in defining new deposits in the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange (‘TSXV’) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Condor Gold {AIM: CNR} is pleased to announce drill results from an initial 2,000 m drill
programme on the Mestiza Vein Set (‘Mestiza’) at La India Project, Nicaragua. The objective is to test an historic, relatively shallow, Soviet mineral resource (2,392 kt at 10.2 g/t gold for 785,694 oz gold).

Drill Results La India Project: 3.3 m at 28.3 g/t gold and 2.65 m at 12.6 g/t gold

Condor Gold {AIM: CNR} is pleased to announce drill results from an initial 2,000 m drill
programme on the Mestiza Vein Set (‘Mestiza’) at La India Project, Nicaragua. The objective is to test an historic, relatively shallow, Soviet mineral resource (2,392 kt at 10.2 g/t gold for 785,694 oz gold).

Initial results from the Tatiana Vein, one of the constituent veins, are excellent.

The programme continues.

.
Highlights:
• LIDC344 drill width 3.3 m (true width 2.2 m) at 28.3 g/t gold and 38.9 g/t silver including
0.95m@75.6 g/t Au. From 76.7 m depth.
• LIDC348 drill width 2.65 m (true width 1.7 m) at 12.6 g/t gold and 21.8 g/t silver including
0.6m@27.7 g/t Au. From 91 m depth.

• The initial 2,000 m drilling is now expanded to 3,000 m.

• The Tatiana vein has excellent continuity for 1.5km and is a 4-5 m wide mineralised
structure.
• High recoveries achieved in vein zone, including mineralised fault breccias that previous
drilling failed to recover.
• Second rig mobilised and has commenced drilling.

.
Mark Child, Chairman and CEO comments: ‘The initial drill results at Mestiza of 3.3 m at 28.3 g/t gold and 2.65 m at 12.6 g/t gold are highly encouraging. The objective is to convert an historic Soviet-style mineral resource of 2,392 kt at 10.2 g/t gold for 785,694 oz gold to Canadian NI 43-101 standard. This will boost the current NI 43-101-compliant Inferred Mineral Resource at Mestiza of 1,490 kt at 7.47 g/t for 333,000 oz gold.”

.
Mestiza is excluded from the current mine plans in the PFS and PEAs. A successful resource conversion has the potential to add large, high grade, and relatively shallow resources to a future mine plan, thereby increasing the annual gold production, life of mine and project economics. The Tatiana vein has excellent continuity for 1.5km and is a 4-5 m wide mineralised structure. In the past few days a second rig has commenced drilling on Mestiza.”

.

.
Background
La India Project’s existing NI 43-101-compliant mineral resource is 18 Mt at 4.0 g/t Au for 2.31 Moz gold. This comprises 7 separate resources, all open along strike and at depth. It includes Mestiza, which hosts a NI 43-101-compliant mineral resource of 1,490 kt at 7.47 g/t for 333,000 oz gold.

.

.
Condor Gold plc

7th Floor
39 St. James’s Street
London
SW1A 1JD

For further information please visit www.condorgold.com

or contact:

Mark Child, Executive Chairman and CEO
020 7493 2734

About Condor Gold plc:
Condor Gold plc was admitted to AIM on 31st May 2006. The Company is a gold exploration and development company with a focus on Central America.
Condor completed a Pre-Feasibility Study (PFS) and two Preliminary Economic Assessments (PEA) on La India Project in Nicaragua in December 2014. The PFS details an open pit gold mineral reserve of 6.9 Mt at 3.0 g/t gold for 675,000 oz gold producing 80,000 oz gold p.a. for 7 years.

The PEA for the open pit only scenario details 100,000 oz gold production p.a. for 8 years whereas the PEA for a combination of open pit and underground details 140,000 oz gold
production p.a. for 8 years. La India Project contains a total attributable mineral resource of 18.08 Mt at 4.0 g/t for 2.31 M oz gold and 2.68 M oz silver at 6.2 g/t to the CIM Code.
In El Salvador, Condor has an attributable 1,004,000 oz gold equivalent at 2.6 g/t JORC compliant resource. The resource calculations are compiled by independent geologists SRK Consulting (UK) Limited for Nicaragua and Ravensgate and Geosure for El Salvador.
Disclaimer
Neither the contents of the Company’s website nor the contents of any website accessible from hyperlinks on the Company’s website (or any other website) is incorporated into, or forms part of, this announcement.

Colonial Coal {TSX.V: CAD} the Canadian based Metallurgical coal exploration and development company has received a buy rating from US based ValuEngine.

ValuEngine has sent out their research report and buy rating to investors.

ValuEngine upgraded shares of Colonial Coal International Corp (TSX.V: CAD) from a hold rating to a buy rating in a research report sent to investors.

Colonial Coal International Corporation  Company Profile

Colonial Coal International Corp. is an exploration-stage company. The Company’s principal activities include acquisition, exploration and development of coal properties located in Canada. Its portfolio projects include Flatbed Coal Project, Tuya River Project and Huguenot Coal Project.

Its Flatbed Coal Project is a metallurgical coal project consisting of approximately eight coal licenses covering a total area of approximately 9,610 hectares.

All of Colonial’s licences are located in the prolific Peace River Coalfield in British Colombia, Canada.

Inovio Pharmaceuticals, Inc. {NASDAQ:INO} today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates
in a Clinical Study

Amongst highest levels of immune responses ever demonstrated
in an HIV vaccine human study

 
PLYMOUTH MEETING, Pa., May 24, 2017 — Inovio Pharmaceuticals, Inc. {NASDAQ:INO} today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.

These preliminary results are from a study supported by the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in collaboration with Inovio. The study evaluated a four-dose regimen of PENNVAX-GP DNA vaccine administered by intradermal (ID) or intramuscular (IM) administration in combination with a DNA encoded immune activator, IL-12 (INO-9012). Overall, 71 of 76 (93%) evaluable vaccinated participants showed a CD4+ or CD8+ cellular immune response to at least one of the vaccine antigens (env A, env C, gag, or pol). Similarly, 62 of 66 (94%) evaluated participants demonstrated an env specific antibody response.

None of the placebo recipients (0 of 9; 0%) demonstrated either a cellular or an antibody response in the study. Notably, amongst the participants receiving PENNVAX-GP vaccine and IL-12 with intradermal immunisation, 27 of 28 (96%) participants demonstrated a cellular response and 27 of 28 (96%) demonstrated an HIV env specific antibody response.

Amongst the evaluated participants receiving PENNVAX-GP and IL-12 via IM vaccination, 27 of 27 (100%) demonstrated a cellular response and 19 of 21 (90%) demonstrated an env specific antibody response. Similar immune responses and response rates were achieved via both ID and IM administration of the vaccine although participants vaccinated via intradermal vaccine administration received 1/5th the dose of vaccine compared to those vaccinated via intramuscular administration.

This breakthrough data was presented at a plenary session at the 2017 HVTN Spring Full Group Meeting on May 23 in Washington, D.C. by the Protocol Co-Chair of the HVTN 098 study, Dr. Stephen De Rosa, Research Associate Professor, Laboratory Medicine at the University of Washington and Fred Hutchinson Cancer Research Center. The HVTN 098 trial was the first clinical study of PENNVAX-GP. The randomized, placebo-controlled multi-center study enrolled 94 subjects (85 vaccine and 9 placebo) to characterize and optimize PENNVAX-GP immunisation regimens delivered through vaccinations using either intramuscular or intradermal delivery.

Dr. De Rosa, said, “The preliminary results of HVTN 098 are remarkable for a number of reasons. In HVTN 098, nearly all individuals vaccinated with the regimens including IL-12 had detectable CD4 responses and over half had CD8 T cell responses. Similarly, the antibody response rate was 100% or close to 100% for several of the env antigens tested in the assay. Thus, these high response rates are exceptional. Further studies will be needed to determine if this vaccine candidate can safely and effectively prevent HIV infection.”

Dr. J. Joseph Kim, Inovio’s President & CEO, said, “These results are among the highest ever responses we’ve seen with an HIV vaccine, and they are remarkably consistent with our recent data reported from our Ebola, Zika and MERS clinical trials in terms of demonstrating nearly 100% vaccine response rates with very favorable safety profile. Furthermore, our newer and more tolerable intradermal vaccine delivery device showed that we can elicit very high immune responses at a much lower dose. We look forward to advancing PENNVAX-GP into later-stage clinical development with our partners and collaborators.”

Development of Inovio’s PENNVAX-GP immunotherapy, which widely targets multiple major clades of HIV — providing global coverage — has been funded through a $25 million NIAID contract previously awarded in 2009 to Inovio and its collaborators. In addition, Inovio and its collaborators were awarded an additional five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant in 2015 from NIAID.

About HIV Infection

Nearly 35 million people have died from HIV-related causes and over 36 million are living with HIV. HIV is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is classified into clades, sub-types within which the virus has genetic similarities. The most prevalent clades are B (found mainly in North America and Europe), A and D (found mainly in Africa), and C (found mainly in Africa and Asia).

HIV clade C accounts for 48% of worldwide and 51% of African-HIV type 1 cases. It is the most rapidly spreading subtype of HIV. Although highly active antiretroviral therapy regimens have dramatically transformed the treatment of the disease in developed countries, safe and effective HIV vaccines are needed to stop the spread of disease.

About Inovio’s PENNVAX® HIV Vaccines and Immunotherapies

Inovio completed initial clinical studies of its HIV immunotherapy PENNVAX-B, targeting clade B viruses, to achieve proof of principle in generating potent immune responses using its SynCon® immunotherapy technology. In two published phase 1 studies, PENNVAX-B immunization via IM injection generated high levels of activated and antigen-specific CD8+ killer T cells. This ability uniquely positions PENNVAX as an important product candidate for both preventing and treating HIV infections.

Using a $25 million contract from the NIH, Inovio designed its universal, multi-clade, multi-antigen PENNVAX-GP immunotherapy targeting the env, gag and pol antigens to provide coverage against all major HIV-1 clades. Inovio’s HIV development focus for both preventive and therapeutic purposes is on PENNVAX-GP.

About the HVTN

The HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, Wash., is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The HVTN’s mission is to facilitate the process of testing preventive vaccines against HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The Network’s HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. Internationally renowned HIV vaccine and prevention researchers lead the units.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favourable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:
Bernie Hertel,

+1 858 410 3101

bhertel@inovio.com

Barkerville Gold Mines Ltd. {TSXV: BGM} announced additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company’s flagship Cariboo Gold Project. The Company is currently exploring and delineating the Valley Zone with four drill rigs. 

Condor Gold {AIM: CNR} has written off its investment in El Salvador, due to the mining moratorium imposed by that country.

This has nearly doubled the reported financial loss for this year.

Drilling at La India, Nicaragua.

Condor Gold’s pre-tax loss almost doubles due to El Salvador write down